Please use this identifier to cite or link to this item:
|Title:||Treatment of bladder cancer with Bi-213-anti-EGFR-MAb – a pilot study|
|Authors:||SCHEIDHAUER Klemens; SEIDL C.; MORGENSTERN Alfred; BRUCHERTSEIFER Frank; APOSTOLIDIS Christos; AUTENRIETH Michael; KURTZ F; ESSLER M.; SCHWAIGER M.; SENEKOWITSCH-SCHMIDTKE R.|
|Citation:||JOURNAL OF NUCLEAR MEDICINE vol. 55 no. Supplement 1 p. 639|
|Publisher:||SOC NUCLEAR MEDICINE INC|
|Type:||Articles in periodicals and books|
|Abstract:||Following transurethral resection of non-muscle-invasive bladder cancer (carcinoma in situ) and subsequent chemotherapy and treatment with Bacillus Calmette–Guérin (BCG), up to 40% of patients relapse within 5 years. Therefore, new therapeutic strategies to combat tumor recurrence are needed. Because treatment of mice bearing intravesical human bladder cancer xenografts with Bi-213-anti-EGFR-MAb turned out highly efficient, the aim of this pilot study was to evaluate therapeutic efficacy of the α-emitter radioimmunoconjugate in bladder cancer patients.|
|JRC Directorate:||Nuclear Safety and Security|
Files in This Item:
There are no files associated with this item.
Items in repository are protected by copyright, with all rights reserved, unless otherwise indicated.